# A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

> **NCT03713242** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** ACT-541468 25 mg
- **DRUG:** ACT-541468 25 mg (or 10 mg depending on interim results)

## Key facts

- **NCT ID:** NCT03713242
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2020-02-27
- **Final completion:** 2020-02-27
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713242, "A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03713242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*